Celldex Therapeutics
CLDX
CLDX
180 hedge funds and large institutions have $1.48B invested in Celldex Therapeutics in 2025 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 75 increasing their positions, 42 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
1.99% less ownership
Funds ownership: 110.92% → 108.93% (-2%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
40% less call options, than puts
Call options by funds: $3.21M | Put options by funds: $5.37M
Holders
180
Holding in Top 10
2
Calls
$3.21M
Puts
$5.37M
Top Buyers
| 1 | +$31.6M | |
| 2 | +$12.2M | |
| 3 | +$8.5M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$8.29M |
| 5 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
+$7.89M |
Top Sellers
| 1 | -$63.5M | |
| 2 | -$48.8M | |
| 3 | -$12.8M | |
| 4 |
State Street
Boston,
Massachusetts
|
-$8.16M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$8.13M |
